Samsung Bioepis Reports Results SB5 (biosimilar, adalimumab) in Two Studies for the Treatment of Behçet’s Syndrome-Related Uveitis and IBD
- The company reported 2 new studies to evaluate adalimumab biosimilar SB5 for IBD including CD & UC and non-anterior uveitis associated with BS
- In a real-world study for IBD, 83.1% of patients switched from the reference product to biosimilar SB5. In the retrospective study on BS-associated uveitis, 8 patients treated with SB5 experienced complete resolution of inflammation @16mos.
- The 1EPs of the study was drug persistence. In the start & switch cohort, 137 patients (77.8%) & 213 patients (84.6%) remained on the biosimilar after 26wks, 65 (60.3%) & 163 (70.8%) were still being treated with SB5 @52wks. At a median follow-up of 18.3mos. & 13.7mos., 81 (36%) & 90 (35.2%) patients discontinued biosimilar treatment while 24 & 46 due to AES & 26 & 37 due to secondary loss of response, 22 due to primary non-response in the start cohort
Ref: Center for Biosimilars | Image: Samsung Bioepis
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected]